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ABSTRACT
Introduction A December 2019 WHO rapid 
communication recommended the use of 9- month all- oral 
regimens for treating multidrug- resistant tuberculosis 
(MDR- TB). Besides the clinical benefits, they are thought to 
be less costly than the injectable- containing regimens, for 
both the patient and the health system. STREAM is the first 
randomised controlled trial with an economical evaluation 
to compare all- oral and injectable- containing 9–11- month 
MDR- TB treatment regimens.
Methods and analysis Health system costs of delivering 
a 9- month injectable- containing regimen and a 9- month 
all- oral bedaquiline- containing regimen will be collected 
in Ethiopia, India, Moldova and Uganda, using ‘bottom- 
up’ and ‘top- down’ costing approaches. Patient costs 
will be collected using questionnaires that have been 
developed based on the STOP- TB questionnaire. The 
primary objective of the study is to estimate the cost utility 
of the two regimens, from a health system perspective. 
Secondary objectives include estimating the cost utility 
from a societal perspective as well as evaluating the cost- 
effectiveness of the regimens, using both health system 
and societal perspectives. The effect measure for the 
cost–utility analysis will be the quality- adjusted life years 
(QALY), while the effect measure for the cost- effectiveness 
analysis will be the efficacy outcome from the clinical trial.
Ethics and dissemination The study has been evaluated 
and approved by the Ethics Advisory Group of the 
International Union Against Tuberculosis and Lung Disease 
and also approved by ethics committees in all participating 
countries. All participants have provided written informed 
consent. The results of the economic evaluation will be 
published in a peer- reviewed journal.
Trial registration number ISRCTN18148631.
BACKGROUND
The STREAM trial is a phase III non- inferiority 
randomised controlled trial (RCT) to test 
the efficacy, safety and economical impact of 
shortened multidrug- resistant tuberculosis 
(MDR- TB) treatment regimens. MDR- TB is a 
form of tuberculosis (TB) caused by bacteria 
that cannot be treated with two of the most 
powerful, first- line anti- TB drugs, isoniazid 
and rifampicin. Globally, in 2017, there were 
a little over half a million people with TB 
resistant to rifampicin, and out of these, 82% 
had MDR- TB.1
The WHO’s End TB Strategy is among the 
health targets of the Sustainable Development 
Goals. It was adopted by the World Health 
Assembly in 2014 with the aim of reducing TB 
deaths by 90% and new cases by 80% between 
2015 and 2030, as well as reducing to zero the 
number of households incurring catastrophic 
costs due to TB by 2020. Currently, global TB 
incidence is falling at 2% per year, which is 
Strengths and limitations of this study
 ► The economic evaluation of STREAM will be the first 
study to estimate the costs incurred by both patients 
undergoing multidrug- resistant tuberculosis treat-
ment and the healthcare system within a phase III 
randomised controlled trial.
 ► The detailed costing and analysis in four differ-
ent settings will provide valuable insights into the 
timings and drivers of the costs associated with 
implementation of a 9- month all- oral bedaquiline- 
containing regimen. The study will generate import-
ant evidence needed for future policy decisions and 
the shaping of targeted interventions.
 ► The trial setting means that additional research 
costs (e.g. costs for collecting pharmacokinetic 
samples, social support costs paid for by the study) 
that would not be incurred in a routine setting will 
be incurred. These research costs will be separat-
ed out and eliminated from the costing analysis. 
Additionally, the experience of participants and 
delivery of health services (e.g. frequency of visits) 
will in places, inevitably deviate from routine prac-
tice, with implications for patient and health system 
costs. Though we will attempt to adjust for these dif-
ferences in analysis, guaranteeing no interference 
may not be possible.
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insufficient to reach the 2020 milestone.2 This means that 
new ways of addressing the disease must be found to meet 
these targets. Careful evaluation of alternative treatment 
strategies is vital to ensure the most effective and feasible 
approaches are implemented.
The December 2019 WHO rapid communication recom-
mends the use of shorter, all- oral, bedaquiline- containing 
regimens for patients with MDR- TB.3 It seems that all- oral 
regimens, as opposed to those containing injectables, are 
becoming the preferred option for treatment of MDR- TB 
as data from the South African TB programme had 
suggested them to improve patient outcomes. Replacing 
the injectable with bedaquiline resulted in better treat-
ment success and better adherence.3 Besides the clinical 
benefits, it is also thought that the all- oral treatment leads 
to lower costs from a health system and patient perspec-
tive.4 It is therefore crucial to test these hypotheses via 
an RCT in multiple settings. Furthermore, to date, no 
phase III trial has included an economic analysis of the 
9- month bedaquiline- containing regimen, making it diffi-
cult for policymakers to assess the economical and finan-
cial impact. STREAM is the first randomised phase III 
trial to include such an analysis, to compare the all- oral, 
bedaquiline- containing and injectable- containing 9–11- 
month MDR- TB treatment regimens.
Objectives
The questions that the economical evaluation is aiming 
to address include:
 ► What are the health system costs of treating patients 
with MDR- TB using the following regimens: a 9- month 
injectable regimen; a 9- month all- oral bedaquiline- 
containing regimen and a 6- month injectable 
regimen?
 ► What costs do patients face during and after treatment?
 ► How does MDR- TB affect patients’ socioeconomic 
situations?
 ► What financial coping mechanisms do patients 
employ?
The primary economical objective is to estimate the 
cost utility of the two MDR- TB interventions, in each 
country, from a health system perspective. To achieve 
this, an economical evaluation of both the costs and 
consequences associated with each intervention will be 
conducted.
Secondary economical objectives include assessing 
the cost utility of the regimens from a societal perspec-
tive and evaluating the cost- effectiveness of the regimens 
from both a health system and societal perspective.
The effect measure for the cost–utility analysis will be the 
QALY, while the effect measure of the cost- effectiveness 
analysis will be the efficacy outcome from the clinical trial 
that is favourable or unfavourable.
METHODS AND ANALYSIS
Randomised controlled trial design
Health economics data will be collected alongside the 
STREAM trial. Its protocol has been published elsewhere.5 
In brief, the STREAM study is an international, multi-
centre, parallel- group RCT of patients with MDR- TB and 
patients with rifampicin- resistant and isoniazid- sensitive 
TB. It will be assessed whether the proportion of partici-
pants on regimen C with a favourable efficacy outcome at 
week 76 is not less on that on regimen B, that is, C is non- 
inferior to B. Data will also be collected on regimen D 
for secondary comparisons. Treatments administered are 
outlined in figure 1 and explained below. Trial recruit-
ment started in April 2016, across 13 sites in 7 countries 
(table 1).
At the start of Stage 2, randomisation was to regimen 
A, regimen B, regimen C and regimen D, in a ratio of 
1:2:2:2, done using a web- based system managed by 
Medical Research Council Clinical Trials Unit (MRC 
CTU). Version 8.0 of the protocol limits randomisation to 
arms B and C, so patients will no longer be randomised to 
regimen A and regimen D and randomisation will be in a 
ratio of 1:1. At least 200 patients to each of regimen B and 
regimen C will be randomised, across all sites. This was 
determined based on the assumption that the proportion 
of patients with a favourable efficacy outcome at week 76 
is 80% for regimen B and 82% for regimen C. With a non- 
inferiority margin of 10% and a one- sided significance 
level of 2.5%, 180 evaluable patients will be required in 
each of the two regimens to demonstrate non- inferiority. 
Figure 1 Treatments outline. Regimen A was dropped of the trial.
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If 10% of patients will be excluded from the primary effi-
cacy analysis population, a total of 400 patients would be 
required in total for regimens B and C5.
The health economic analysis will include participants 
of the clinical trial in the above- mentioned sites, who 
are over 18 years old and fulfil the inclusion/exclusion 
criteria as outlined in the trial protocol. All patients in the 
study will be followed up until week 132, with the primary 
analysis conducted on data collected up to week 76.
Patient data will be collected at 12- week intervals, 
during the patient assessment visits for the clinical trial, 
using a questionnaire developed based on the STOP- TB 
questionnaire, in all health economic sites.
Health system cost data will be collected by the focal 
health economists in each country during the whole trial 
period.
The Consolidated Health Economic Evaluation 
Reporting Standards checklist has been used as a guide to 
optimise the preparation and reporting of the methods 
used (online supplemental annex 1).
Health system resource use and costs
A mixture of top- down and bottom- up approaches will be 
used.
Data regarding staff time and staff activities involved in 
the management of MDR- TB treatment for each regimen 
will be collected by the focal health economists in each 
country using a standardised questionnaire developed by 
the health economic team, pilot tested in all HE sites and 
used in the first phase of the trial.6
A full assessment of the health system costs of deliv-
ering the MDR- TB regimens, including tests performed, 
consumables used, inpatient stay costs, drugs administered 
and overheads, will be done in each country, for each 
arm. Any relevant resource events will also be included. 
These will be collected by the focal health economists in 
each country using hospitals’ accounting records, clinical 
trial casa report forms (CRFs) and STREAM protocol, 
and will be costed using local unit costs where possible. 
Where this will not be possible, STREAM or in- country 
private healthcare facilities unit costs will be used.
The costs associated with the diagnosis and manage-
ment of serious adverse events caused by MDR- TB or its 
treatment will also be included. The costing will include 
all tests performed, examinations, investigations, inpa-
tient stays and medication received, as well as staff costs. 
Data will be collected in an event costing tool developed 
in Microsoft Excel by the HE trial team and the main data 
source will be the clinical trial CRFs.
The total health system costs for each trial arm will be 
estimated by summing the costs of each resource used 
and presented by the following cost elements, by phase 
(see table 2).
Capital costs extending beyond 1 year (eg, equipment) 
will be annualised over their expected lifespan assuming 
a discount rate of 3%.
Research costs such as costs related to the pharmaco-
kinetics study will not be collected or included in this 
economic evaluation. The health system costing will 
be done in close collaboration with the central health 
economic team to make sure it is sensible and evaluated 
with the support of a team of clinicians involved in the 
clinical trial. If deemed appropriate, other research costs 
that do not reflect usual practice will be excluded.
Patient costs
Patient costs will be collected by administering question-
naires that have been developed based on the STOP- TB 
questionnaire.7 Data will be collected in two stages. First, 
a baseline questionnaire will capture socioeconomic 
data of each patient before they start treatment. Then, 
a follow- up questionnaire capturing any changes to the 
socioeconomic data and a patient treatment cost ques-
tionnaire will be administered every 12 weeks.
The patient costs to be collected are presented in 
table 3.
The total direct cost per participant receiving MDR- TB 
treatment will be calculated as follows:
 
 
Total direct cost =
(
CostDots ∗ NoVisitsD
)
+
(
CostSVisits ∗ NoVisitsS
)
+(
CostUVisit ∗ NoVisitsU
)
+ CostSupp  
 
where NoVisitsD, NoVisitsS, NoVisitsU=number of visits 
for attending DOTs, scheduled and unscheduled visits, 
respectively.
Usually, patients with TB are accompanied by a guardian 
to the direct observed treatment (DOT) and/or assess-
ment visits. The guardians’ direct costs (transport, food 
and accommodation costs) for each patient and for each 
visit will be included in the patient–costs analysis. Patients 
Table 1 STREAM trial sites
Clinical trial sites HE sites
Mongolia National Center for Communicable 
Diseases, Ulaanbaatar
  
Ethiopia Armauer Hansen Research Institute, 
Addis Ababa
x
St. Peter’s Hospital, Addis Ababa x
South 
Africa
King Dinuzulu Hospital, Durban   
Helen Joseph Hospital, Johannesburg   
Empilweni TB Hospital, Port Elizabeth   
Doris Goodwin, Pietermaritzburg   
Moldova IMSP, Chiril Draganiuc, Chisinau x
Uganda Mulago Hospital, Kampala x
Georgia National Center for Tuberculosis and 
Lung Disease, Tbilisi
  
India B.J. Medical College, Ahmedabad x
National Institute for Research in 
Tuberculosis, Chennai
x
Rajan Babu Institute for Pulmonary 
Medicine and Tuberculosis, Delhi
x
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who indicate they had a ‘guardian’ during treatment will 
be asked whether this guardian lost an income when 
accompanying them; their lost time will be assumed to 
equal the patient’s and valued at the national minimum 
wage.
All participants, conditional on survival to week 76, 
will be included in the primary analysis. In the secondary 
analysis, all modified intention to treat participants will 
be included, treating missing answers as missing data 
and handled as explained in the missing data section 
below.
All costs will be collected in the local currency and 
converted to US$ using the exchange rate reported by 
OANDA8 at the time of the analysis. All costs will be 
inflated to 2021 prices.
Due to logistics issues, data collection for the health 
economic component was delayed at two Indian sites, 
Ahmedabad and Chennai, and the Ugandan site, so 
baseline and week 12 patient data will be collected at the 
week 24 or week 36 visit for the first patients enrolled 
into the trial. This will be subject to sensitivity analysis. All 
interviews after week 36 will be conducted as scheduled, 
during the patient assessment visits.
The analysis will be performed in Stata (Stata, USA) 
and for each cost category, descriptive statistics (mean, 
median, SE and IQR) will be presented.
Quality assurance exercises will be carried out regularly 
during data collection by the central Health Economics 
team, to assess the logic and credibility of responses. 
Feedback will be provided to data collection staff on any 
Table 2 Health system costs sources and calculation methods
Cost element Unit
Data sources
MethodCosts sources
Quantity used per 
treatment phase 
(intensive, continuation 
and follow- up until 
week 76)
Inpatient stay Cost per day Local hospitals' 
accounting records or 
local private facilities if 
not available
Actual number of 
inpatient stay days for all 
patients
Unit cost per day multiplied 
by the number of inpatient 
days for each patient
Laboratory tests Cost per test Local hospitals' 
laboratories or local 
private facilities if not 
available
Frequency from the 
STREAM trial protocol
Cost per test multiplied 
by the number of tests 
performed for each patient
Medication Unit cost per tablet/
dose
Local hospitals' 
pharmacies purchasing 
lists
(alternative drug price lists 
if not available locally)
Dosages, treatment 
interruptions, etc, from 
the STREAM trial clinical 
CRFs
Unit cost per dose multiplied 
by the total number of doses 
for each patient
Staff Cost per minute Local pay scales Time collected using staff 
questionnaire
Unit cost per minute 
multiplied by number of 
minutes in a visit multiplied 
by number of total visits
Social support Cost per week TB national programme TB national programme Cost per week times number 
of weeks the patient is 
eligible for social support
Consumables Per patient per visit Local hospitals' 
pharmacies purchasing 
lists or local private 
pharmacies
Quantity of each unit 
collected via direct 
observation and staff 
questionnaire
Unit cost per patient per visit 
multiplied by the number of 
visits.
Serious adverse 
events (SAEs)
Per patient per SAE A combination of all the 
above
A combination of all the 
above
Unit costs of: consumables, 
lab tests, medication, staff 
will multiplied by the quantity 
of each to calculate the cost 
of managing each SAE
Overheads Overhead costs per 
patient per day
As reported by the local 
hospitals accounting 
records
As reported by the local 
hospitals. Number of 
patients in the TB unit will 
be used as a proxy.
Total overhead costs will be 
calculated for the TB unit 
over a year, then divided by 
the number of patients with 
TB in a year
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issues raised from the exercise, so that they could correct 
and improve their guidance to participants during data 
collection.
Health-realted Quality ofLife measurement
For the primary outcome calculations, patient health 
states will be measured prospectively using the EQ- 5D- 5L9 
every 12 weeks from week 0 (i.e. baseline), before the 
patient takes the first drug, until week 76. The responses 
to the questionnaire will be converted into health utility 
scores using the most appropriate tariff for each country, 
selected based on geographical proximity and econom-
ical context. Currently, the tariffs that we propose to use 
are from Indonesia (for India), Ethiopia (for Ethiopia 
and Uganda) and Poland (for Moldova) and can be seen 
in online supplemental annex 2. We will use updated 
value sets if these become available before the analysis 
stage. The value sets will be used to calculate the HRQoL 
for each patient at each interview point. Observations 
for each patient will be combined to calculate a QALY 
score for each arm using the ‘area under the curve’ linear 
method, using the formula below:
 
QALY =
∑[ (Ui+Ui+1)
2
]
×
(
ti+1 − ti
)
 
where U=utility value and t=time between interviews.
QALY calculations will also account for mortality during 
the follow- up period, by assigning 0 QALYs from time of 
death until the end of follow- up.
The health system costs will be calculated on a per 
patient basis and together with the QALY outcome will be 
used to calculate the incremental cost- effectiveness ratio 
(ICER) of regimen C to regimen B, using the formula 
below:
 
ICER =
(
CostRegimenC−CostRegimenB
)
(
Mean QALYRegimenC−Mean QALYRegimenB
)
 
Cost- effectiveness acceptability curves will be 
constructed to compare the regimens’ probabilities 
of being cost- effective against a set of pre- set threshold 
values, ranging from US$0 to US$100 000 and including 
some published estimates.10
Secondary objectives
Secondary objectives will consider the primary clinical 
outcome in the clinical trial. This is a favourable outcome, 
where a participant had their last two culture results, 
taken on separate visits but no more than 6 weeks earlier 
than week 76, negative or an unfavourable outcome.
For the societal perspective analyses, direct patient 
costs data collected as explained above will be added to 
the health system costs to calculate the societal costs.
Subgroup analyses
We will present data disaggregated by age, sex, HIV status, 
site and other variables may be presented where they will 
be identified in the study as potentially relevant.
Missing data
The nature and pattern of missing data will be analysed. 
If necessary, multiple imputation techniques11 will be 
used to address the missing data in the base case, by 
using relevant baseline variables. This method is recom-
mended for economical evaluations alongside clinical 
trials.12 Other methods such as complete case analysis, 
average imputation, lowest and highest point imputa-
tion and listwise deletion will be tested in the sensitivity 
analysis.
Table 3 Patient cost data collection method and analysis plan
Cost type Data collection method Analysis
Cost of attending direct observed 
treatment (DOTs) (CostDots)
Through patient CRFs (transport 
and food costs data)
For each cost type category, data will be aggregated 
for each site and arm, to estimate the mean direct 
cost per visitCosts of attending injection DOTs 
(CostDots)
Through patient CRFs (transport 
and food costs data)
Patient cost for attending 
scheduled patient assessment 
visits (CostSVisits)
Through patient CRFs (transport 
and food costs data)
Patient costs for attending 
unscheduled patient assessment 
visits (CostUVisits)
Through patient CRFs (transport 
and food costs data)
Food supplements (CostSupp) Through patient CRFs Mean spend for each time point to be calculated 
and presented as the cumulative difference in food 
purchases between arms
Income loss during and after 
treatment
Reported by patients if willing to 
reveal their income at each time 
point; if not, working hours reported 
to be used as a proxy
If patients are unwilling to reveal their income, 
average salary values from the specific areas in each 
country will be used. The total lost hours will be 
multiplied with the hourly average wage. Total income 
loss during treatment and follow- up will be calculated
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Statistical analysis
We will present our results in terms of precision, that is, 
how close the data are expected to be to the true popu-
lation value, presenting means and SD of the results. 
95% CI ranges will be constructed and presented such 
that there is a 95% probability that the results will contain 
the true population parameter.13
Sensitivity analyses
Sensitivity analyses will be used to test the robustness of 
the results. Planned sensitivity analyses can be seen in 
table 4 ; however, any other things that become important 
will also be tested.
A non- parametric bootstrapping approach will be 
used to determine the level of sampling uncertainty 
surrounding the mean ICER by generating 1000 esti-
mates of incremental costs and outcomes. These will be 
presented on a cost- effectiveness plane. CIs of the gener-
ated ICERs will then be calculated, in order to summarise 
the uncertainty due to sampling variations.
Net monetary benefit (NMB) will be calculated for 
each bootstrap estimate for a range of cost- effectiveness 
thresholds as follows:
 NMB =
(
λ∗QALYs
)
− Costs 
where λ represents the cost- effectiveness threshold. This 
will be calculated as one to three times Gross Domestic 
Product (GDP) per capita, and other thresholds from 
country guidance or the literature. The regimen with 
NMB>0 or with the highest NMB should be adopted. 
Mean NMB will be reported with 95% bootstrap CIs and 
z- test conducted.
Patient and public involvement
WHO’s End TB Strategy includes policy goals around 
elimination of patient catastrophic costs, and this study 
has been developed to measure and inform both public 
and stakeholders regarding the economical impact of 
MDR- TB on patients.
The health economic research questions were devel-
oped based on the STOP- TB questionnaire by the health 
economic team involved in conducting the study at 
Liverpool School of Tropical Medicine and University 
of Warwick, based on clinical practice, trial protocol and 
literature review. All health economic questionnaires 
have been pilot tested with opportunity for patients to 
give feedback.
Community advisory boards (CABs), comprised of 
volunteers from (among others) community- based organ-
isations, those affected by TB and sometimes trial team 
members, are functioning with the support of the trial at 
all 13 STREAM Stage 2 sites. Most CABs were formed at 
site initiation and, therefore, did not inform the devel-
opment of the research question and outcome measures; 
however, input on the trial protocol was received from the 
Global TB CAB. The STREAM CABs act as coordinating 
mechanisms for community engagement at STREAM 
trial sites. Their activities include community outreach 
(engaging the local communities and key populations 
to raise awareness and literacy on MDR- TB, research, 
and the trial), provision of psychosocial support to study 
patients and advocacy activities aimed at improving 
programmes and policies. The CABs also meet regularly 
with their respective study teams for trial updates and to 
pass on patient and community feedback from the trial. 
Results of the trial will be disseminated to participants 
and affected communities, with the support of STREAM 
CABs, likely at outreach events for participants and their 
families.
The burden of the intervention will be assessed by the 
patients taking part in the health economic component 
of the trial, through the EQ- 5D- 5L questionnaire, which 
is a self- reported measure of quality of life. These patients 
Table 4 Planned sensitivity analyses
Parameters Rationale/method
Complete- case analysis, Average imputation, 
lowest and highest point imputation
If the level of missing observations for costs and HRQoL is higher than 10%, 
the MI technique is more prone to bias. Data sets will be analysed to assess 
whether the results indicate similar conclusions
Patient data collected retrospectively in India 
and Uganda
As some data have been collected retrospectively during the trial due to 
logistics issues, two data sets, one including the retrospectively collected data 
(where recall bias might have occurred) and one excluding it, will be analysed 
to assess whether the results indicate similar conclusions.
On the most important cost drivers Unit costs will vary across different sites in the same country. Therefore, 
deterministic sensitivity analysis will be conducted to assess whether the 
results change as unit costs of the most important cost drivers are varied 
within plausible ranges.
Parameter uncertainty Probabilistic sensitivity analysis to explore uncertainties surrounding key 
parameters; 1000 simulations will be run, and results presented as mean costs 
and QALYs.
Inpatient stay Since 2011, WHO recommends outpatient models of care for patients with 
multidrug- resistant tuberculosis. The analysis will be re- run excluding inpatient 
stay costs
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will also assess the economic impact the disease had, by 
reporting changes in income and employment status 
throughout the study.
COVID-19 impact
Also, the COVID-19 outbreak started during the trial. 
Lockdown has been imposed on 18th March in Uganda 
and on 24th March in India, while Moldova and Ethi-
opia declared state of emergency in March 2020. It is 
expected that the COVID-19 mitigating measures taken 
in most countries will affect the socioeconomic status 
of the patients and their quality of life, independent of 
their MDR- TB or MDR- TB treatment.14 There are a few 
measures that will be taken to record this. A COVID-19 
diary, containing information about the lockdown restric-
tions, will be completed by each site (see online supple-
mental annex 3). Also, an additional questionnaire has 
been developed to further explore some of the answers 
regarding their income, spending and health- related 
quality of life.
As data collection started in 2016, before the outbreak, 
the lockdown imposed will be modelled as an indepen-
dent explanatory variable for parameters such as quality 
of life, working hours and supplements spending during 
intensive, continuation and post- treatment phase. If the 
variable turns out to be significant, we will use it to adjust 
values reported post pandemic, using model predictions 
of what would have been reported if the pandemic hadn’t 
happened.
Additional changes to the protocol as a result of 
COVID-19 may be implemented as needed.
DISCUSSION
STREAM will be the first study to estimate the costs 
incurred by both patients undergoing MDR- TB treatment 
and the healthcare system within a phase III RCT.
The detailed costing and analysis in four different 
settings will provide insights into the timing and drivers 
of the cost saving or dissaving of implementing a 9- month 
all- oral bedaquiline- containing regimen, providing the 
data for targeted interventions if needed.
The study will have certain limitations. The EQ- 5D- 5L is 
not a condition- specific measure, and so may miss differ-
ences in symptoms that are important to participants. 
Also, our method assumes a linear relationship between 
values at different time points; however, this might not 
be accurate. It was considered not feasible to ask partici-
pants to complete the EQ- 5D- 5L questionnaire at a more 
frequent interval, that is, each DOT visit.
The trial setting also means that the experience of 
participants might be different from routine practice, in 
ways that could influence costs, such as the frequency of 
visits and their location and the provision of support (eg, 
transport vouchers, food vouchers).
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